vs

Side-by-side financial comparison of FREQUENCY ELECTRONICS INC (FEIM) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

FREQUENCY ELECTRONICS INC is the larger business by last-quarter revenue ($17.1M vs $12.5M, roughly 1.4× Avidity Biosciences, Inc.). FREQUENCY ELECTRONICS INC runs the higher net margin — 10.5% vs -1398.3%, a 1408.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 8.3%). FREQUENCY ELECTRONICS INC produced more free cash flow last quarter ($-1.1M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 11.8%).

Ultra Electronics Holdings is a British defence and security company. It was listed on the London Stock Exchange and was a constituent of the FTSE 250 Index until it was acquired by Cobham, which is itself owned by Advent International.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FEIM vs RNA — Head-to-Head

Bigger by revenue
FEIM
FEIM
1.4× larger
FEIM
$17.1M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+425.8% gap
RNA
434.0%
8.3%
FEIM
Higher net margin
FEIM
FEIM
1408.8% more per $
FEIM
10.5%
-1398.3%
RNA
More free cash flow
FEIM
FEIM
$155.7M more FCF
FEIM
$-1.1M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
11.8%
FEIM

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
FEIM
FEIM
RNA
RNA
Revenue
$17.1M
$12.5M
Net Profit
$1.8M
$-174.4M
Gross Margin
38.2%
Operating Margin
10.0%
-1513.5%
Net Margin
10.5%
-1398.3%
Revenue YoY
8.3%
434.0%
Net Profit YoY
-32.1%
-117.0%
EPS (diluted)
$0.18
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FEIM
FEIM
RNA
RNA
Q4 25
$17.1M
Q3 25
$13.8M
$12.5M
Q2 25
$20.0M
$3.8M
Q1 25
$18.9M
$1.6M
Q4 24
$15.8M
$3.0M
Q3 24
$15.1M
$2.3M
Q2 24
$15.6M
$2.0M
Q1 24
$13.7M
$3.5M
Net Profit
FEIM
FEIM
RNA
RNA
Q4 25
$1.8M
Q3 25
$634.0K
$-174.4M
Q2 25
$3.2M
$-157.3M
Q1 25
$15.4M
$-115.8M
Q4 24
$2.7M
$-102.3M
Q3 24
$2.4M
$-80.4M
Q2 24
$2.6M
$-70.8M
Q1 24
$130.0K
$-68.9M
Gross Margin
FEIM
FEIM
RNA
RNA
Q4 25
38.2%
Q3 25
36.8%
Q2 25
37.5%
Q1 25
43.8%
Q4 24
48.2%
Q3 24
44.4%
Q2 24
40.3%
Q1 24
22.6%
Operating Margin
FEIM
FEIM
RNA
RNA
Q4 25
10.0%
Q3 25
2.6%
-1513.5%
Q2 25
16.4%
-4448.7%
Q1 25
18.3%
-8360.9%
Q4 24
16.5%
-4069.6%
Q3 24
15.7%
-4200.9%
Q2 24
16.0%
-4040.4%
Q1 24
-3.4%
-2178.6%
Net Margin
FEIM
FEIM
RNA
RNA
Q4 25
10.5%
Q3 25
4.6%
-1398.3%
Q2 25
16.0%
-4089.3%
Q1 25
81.4%
-7360.0%
Q4 24
16.8%
-3439.5%
Q3 24
16.1%
-3441.7%
Q2 24
16.9%
-3461.8%
Q1 24
0.9%
-1943.4%
EPS (diluted)
FEIM
FEIM
RNA
RNA
Q4 25
$0.18
Q3 25
$0.07
$-1.27
Q2 25
$0.33
$-1.21
Q1 25
$1.60
$-0.90
Q4 24
$0.28
$-0.80
Q3 24
$0.25
$-0.65
Q2 24
$0.28
$-0.65
Q1 24
$0.01
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FEIM
FEIM
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$3.0M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$58.5M
$1.9B
Total Assets
$92.3M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FEIM
FEIM
RNA
RNA
Q4 25
$3.0M
Q3 25
$4.5M
$350.2M
Q2 25
$4.7M
$243.9M
Q1 25
$5.5M
$254.2M
Q4 24
$9.7M
$219.9M
Q3 24
$16.2M
$370.2M
Q2 24
$18.3M
$575.8M
Q1 24
$11.7M
$471.4M
Stockholders' Equity
FEIM
FEIM
RNA
RNA
Q4 25
$58.5M
Q3 25
$56.3M
$1.9B
Q2 25
$55.6M
$1.2B
Q1 25
$51.8M
$1.3B
Q4 24
$36.2M
$1.4B
Q3 24
$33.2M
$1.5B
Q2 24
$39.8M
$1.2B
Q1 24
$36.7M
$830.9M
Total Assets
FEIM
FEIM
RNA
RNA
Q4 25
$92.3M
Q3 25
$93.2M
$2.1B
Q2 25
$93.7M
$1.4B
Q1 25
$86.4M
$1.5B
Q4 24
$77.8M
$1.6B
Q3 24
$84.3M
$1.6B
Q2 24
$83.3M
$1.3B
Q1 24
$77.7M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FEIM
FEIM
RNA
RNA
Operating Cash FlowLast quarter
$-523.0K
$-156.2M
Free Cash FlowOCF − Capex
$-1.1M
$-156.9M
FCF MarginFCF / Revenue
-6.6%
-1257.6%
Capex IntensityCapex / Revenue
3.6%
5.7%
Cash ConversionOCF / Net Profit
-0.29×
TTM Free Cash FlowTrailing 4 quarters
$-5.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FEIM
FEIM
RNA
RNA
Q4 25
$-523.0K
Q3 25
$1.2M
$-156.2M
Q2 25
$-155.0K
$-199.7M
Q1 25
$-3.6M
$-124.8M
Q4 24
$3.8M
$-99.9M
Q3 24
$-1.5M
$-65.6M
Q2 24
$7.5M
$-65.0M
Q1 24
$4.2M
$-70.4M
Free Cash Flow
FEIM
FEIM
RNA
RNA
Q4 25
$-1.1M
Q3 25
$385.0K
$-156.9M
Q2 25
$-786.0K
$-203.0M
Q1 25
$-4.0M
$-128.6M
Q4 24
$3.3M
$-103.8M
Q3 24
$-1.8M
$-67.3M
Q2 24
$6.7M
$-65.5M
Q1 24
$3.9M
$-71.3M
FCF Margin
FEIM
FEIM
RNA
RNA
Q4 25
-6.6%
Q3 25
2.8%
-1257.6%
Q2 25
-3.9%
-5277.1%
Q1 25
-20.9%
-8174.3%
Q4 24
20.8%
-3491.0%
Q3 24
-11.8%
-2881.8%
Q2 24
42.8%
-3204.6%
Q1 24
28.4%
-2012.3%
Capex Intensity
FEIM
FEIM
RNA
RNA
Q4 25
3.6%
Q3 25
5.6%
5.7%
Q2 25
3.2%
86.9%
Q1 25
1.7%
238.6%
Q4 24
3.3%
131.7%
Q3 24
2.2%
72.9%
Q2 24
5.3%
26.0%
Q1 24
2.3%
25.8%
Cash Conversion
FEIM
FEIM
RNA
RNA
Q4 25
-0.29×
Q3 25
1.83×
Q2 25
-0.05×
Q1 25
-0.24×
Q4 24
1.44×
Q3 24
-0.60×
Q2 24
2.85×
Q1 24
32.36×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FEIM
FEIM

POC Revenue$14.8M86%
POT Revenue$2.3M13%

RNA
RNA

Segment breakdown not available.

Related Comparisons